Bei B. Zhang

发表

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

G. Scapin, N. Thornberry, R. S. Roy, 2005, Journal of medicinal chemistry.

Hypothalamic insulin signaling is required for inhibition of glucose production

L. Rossetti, G. Karkanias, S. Obici, 2002, Nature Medicine.

FGF21 Analogs of Sustained Action Enabled by Orthogonal Biosynthesis Demonstrate Enhanced Antidiabetic Pharmacology in Rodents

Margaret S. Wu, D. Zaller, Thea C. Norman, 2012, Diabetes.

Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes

Margaret S. Wu, Michael E. Lassman, M. Tota, 2011, Proceedings of the National Academy of Sciences.

Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor gamma (PPARgamma), decreases inhibitory serine phosphorylation of IRS1 in vitro and in vivo.

S. Biswas, Bei B. Zhang, Zhihua Li, 2004, The Biochemical journal.

Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization.

S. O’Rahilly, J. Berger, D. Moller, 2002, Endocrinology.

Bombesin receptor subtype-3 (BRS-3) regulates glucose-stimulated insulin secretion in pancreatic islets across multiple species.

M. Reitman, J. Metzger, Yun-ping Zhou, 2011, Endocrinology.

Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1.

Margaret S. Wu, T. Doebber, D. Szalkowski, 2005, The Journal of clinical investigation.

Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.

Nadine H. Elowe, Brian T. Campbell, J. Berger, 2017, Bioorganic & medicinal chemistry letters.

A novel series of indazole-/indole-based glucagon receptor antagonists.

S. Qureshi, Bei B. Zhang, G. Salituro, 2015, Bioorganic & medicinal chemistry letters.

Development of a novel GLUT4 translocation assay for identifying potential novel therapeutic targets for insulin sensitization.

M. Ferrer, J. Berger, F. Santini, 2009, The Biochemical journal.

Stimulation of Glucose-Dependent Insulin Secretion by a Potent, Selective sst3 Antagonist.

Margaret S. Wu, Yun-ping Zhou, A. Howard, 2012, ACS medicinal chemistry letters.

A Genome-Wide siRNA Screen to Identify Modulators of Insulin Sensitivity and Gluconeogenesis

Xiaohua Douglas Zhang, M. Ferrer, Kenny K. Wong, 2012, PloS one.

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

D. Moller, N. Thornberry, S. Conarello, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor γ (PPAR γ ), decreases inhibitory serine phosphorylation of IRS1 invitro and invivo

Bei B. Zhang, Li Zhihua, Q. Dallas-yang, 2003 .

Design and synthesis of conformationally constrained tri-substituted ureas as potent antagonists of the human glucagon receptor.

V. Ding, Bei B. Zhang, J. Tata, 2007, Bioorganic & medicinal chemistry letters.

Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists.

V. Ding, S. Qureshi, K. Chapman, 2005, Bioorganic & medicinal chemistry letters.

Decreased insulin receptor (IR) autophosphorylation in fibroblasts from patients with PCOS: effects of serine kinase inhibitors and IR activators.

Joseph L Evans, J. Youngren, I. Goldfine, 2002, The Journal of clinical endocrinology and metabolism.

Salicylic Acid Reverses Phorbol 12-Myristate-13-Acetate (PMA)- and Tumor Necrosis Factor α (TNFα)-induced Insulin Receptor Substrate 1 (IRS1) Serine 307 Phosphorylation and Insulin Resistance in Human Embryonic Kidney 293 (HEK293) Cells*

D. Moller, Bei B. Zhang, Franklin Liu, 2003, The Journal of Biological Chemistry.

A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects.

D. Moller, V. Ding, S. Qureshi, 2004, Diabetes.

Discovery of potent, orally active benzimidazole glucagon receptor antagonists.

V. Ding, S. Qureshi, D. Szalkowski, 2008, Bioorganic & medicinal chemistry letters.

Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor.

V. Ding, S. Qureshi, D. Szalkowski, 2005, Bioorganic & medicinal chemistry letters.

Cloning and expression of canine glucagon receptor and its use to evaluate glucagon receptor antagonists in vitro and in vivo.

J. Berger, S. Qureshi, Bei B. Zhang, 2007, European journal of pharmacology.

Peroxisome Proliferator-Activated Receptor (PPAR)-α Agonism Prevents the Onset of Type 2 Diabetes in Zucker Diabetic Fatty Rats: A Comparison with PPARγ Agonism

J. Berger, D. Moller, T. Doebber, 2006 .

(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

G. Scapin, Suresh B. Singh, N. Thornberry, 2007, Bioorganic & medicinal chemistry letters.

Anti-Diabetic Efficacy and Impact on Amino Acid Metabolism of GRA1, a Novel Small-Molecule Glucagon Receptor Antagonist

Margaret S. Wu, S. Qureshi, J. Mu, 2012, PloS one.

Optimization of 1,4-diazepan-2-one containing dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes.

N. Thornberry, B. Leiting, G. Eiermann, 2007, Bioorganic & medicinal chemistry letters.

Detection of Glucagon-Dependent GTPγS Binding in High-Throughput Format

S. Qureshi, Bei B. Zhang, Q. Dallas-yang, 2002 .

Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists.

J. Fenyk-Melody, S. Qureshi, D. Szalkowski, 2004, European journal of pharmacology.

Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes.

S. Qureshi, S. Xu, Bei B. Zhang, 2012, Journal of medicinal chemistry.

Evidence that inhibition of insulin receptor signaling activity by PC-1/ENPP1 is dependent on its enzyme activity.

I. Wang, J. Berger, P. Lu, 2009, European journal of pharmacology.

Suppression of PC-1/ENPP-1 expression improves insulin sensitivity in vitro and in vivo.

Margaret S. Wu, I. Wang, J. Berger, 2009, European journal of pharmacology.

Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis.

H. Wilkinson, D. Szalkowski, Howard Y. Chen, 2003, Molecular endocrinology.

Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists.

D. Gerhold, D. Holder, J. Berger, 2002, Endocrinology.

Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2- (2,5-difluorophenyl)-5-(4,6-dihydropyrrolo [3,4-c]pyrazol-5-(1H)-yl)tetrahydro-2H-pyran-3-amine (23) [corrected].

Ping Chen, G. Scapin, R. S. Roy, 2013, Bioorganic & medicinal chemistry letters.

A miniaturized cell-based fluorescence resonance energy transfer assay for insulin-receptor activation.

Shane D. Marine, Erica M. Stec, M. Ferrer, 2006, Analytical biochemistry.

Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.

V. Ding, S. Qureshi, K. Chapman, 2011, Bioorganic & medicinal chemistry letters.

Discovery of N-aryl-2-acylindole human glucagon receptor antagonists.

V. Ding, S. Qureshi, D. Szalkowski, 2011, Bioorganic & medicinal chemistry letters.

Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists.

V. Ding, S. Qureshi, D. Szalkowski, 2011, Bioorganic & medicinal chemistry letters.

Regulation of insulin signal transduction pathway by a small-molecule insulin receptor activator.

D. Moller, D. E. Biazzo-Ashnault, V. Ding, 2002, The Biochemical journal.

Diamine Derivatives as Novel Small-Molecule, Potent, and Subtype-Selective Somatostatin SST3 Receptor Agonists.

Yun-ping Zhou, E. Sherer, A. Howard, 2014, ACS medicinal chemistry letters.

The Role of Voltage-Gated Potassium Channels Kv2.1 and Kv2.2 in the Regulation of Insulin and Somatostatin Release from Pancreatic Islets

M. Jensen, C. Newgard, Yun-ping Zhou, 2013, The Journal of Pharmacology and Experimental Therapeutics.

A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors.

J. Berger, Gaochao Zhou, Bei B. Zhang, 2009, Bioorganic & medicinal chemistry letters.

Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.

J. Berger, Gaochao Zhou, Bei B. Zhang, 2009, Bioorganic & medicinal chemistry letters.

Investigation of Cardiovascular Effects of Tetrahydro-β-carboline sstr3 antagonists.

Margaret S. Wu, M. Reibarkh, Yun-ping Zhou, 2014, ACS medicinal chemistry letters.

Design and synthesis of a new class of malonyl-CoA decarboxylase inhibitors with anti-obesity and anti-diabetic activities.

Margaret S. Wu, Michael E. Lassman, J. Berger, 2010, Bioorganic & medicinal chemistry letters.

Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.

Nadine H. Elowe, Brian T. Campbell, J. Berger, 2017, Bioorganic & medicinal chemistry letters.

Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.

J. Berger, Gaochao Zhou, Sanjeev Kumar, 2009, Journal of medicinal chemistry.

Direct observation (NMR) of the efficacy of glucagon receptor antagonists in murine liver expressing the human glucagon receptor.

V. Ding, Bei B. Zhang, G. Kaczorowski, 2006, Bioorganic & Medicinal Chemistry.

Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes

Yue Feng, Yun-ping Zhou, D. Moller, 2006, Diabetes.

The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes.

Margaret S. Wu, Rebecca T. Ruck, M. Reibarkh, 2012, ACS medicinal chemistry letters.

Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity

E. Air, S. Woods, S. Conarello, 2002, Nature Medicine.

Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.

Kathy Lyons, Ping Chen, Dennis Feng, 2014, Journal of medicinal chemistry.

Glucagon and regulation of glucose metabolism.

Bei B. Zhang, Guoqiang Jiang, Bei B Zhang, 2003, American journal of physiology. Endocrinology and metabolism.

Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator.

Bruce A. Johnson, J. Berger, D. Moller, 2003, Molecular endocrinology.

Gene Expression Profile of Adipocyte Differentiation and Its Regulation by Peroxisome Proliferator-Activated Receptor-γ Agonists.

Ansuman Bagchi, Alex Elbrecht, Arthur Fridman, 2002, Endocrinology.

L-764406 Is a Partial Agonist of Human Peroxisome Proliferator-activated Receptor γ

J. Berger, D. Moller, Gaochao Zhou, 1999, The Journal of Biological Chemistry.

Novel Peroxisome Proliferator-activated Receptor (PPAR) γ and PPARδ Ligands Produce Distinct Biological Effects*

Margaret S. Wu, Y. Li, M. D. Leibowitz, 1999, The Journal of Biological Chemistry.

Role of Skeletal Muscle in Thiazolidinedione Insulin Sensitizer ( PPAR g Agonist ) Action

Margaret S. Wu, J. Berger, D. Moller, 1998 .

Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization.

S. O’Rahilly, J. Berger, D. Moller, 2002, Endocrinology.

Obesity and genetics regulate microRNAs in islets, liver, and adipose of diabetic mice

B. Yandell, E. Schadt, M. Cleary, 2009, Mammalian Genome.

Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor

Lois E. H. Smith, Samuel E. Driver, S. Soker, 1999, Nature Medicine.

Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.

Yun-ping Zhou, N. Thornberry, J. Mu, 2009, European journal of pharmacology.

Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines.

G. Scapin, N. Thornberry, R. S. Roy, 2008, Journal of medicinal chemistry.

AMPK: an emerging drug target for diabetes and the metabolic syndrome.

Gaochao Zhou, Bei B. Zhang, Cai Li, 2009, Cell metabolism.

Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists.

Margaret S. Wu, J. Berger, D. Moller, 2002, Diabetes.

Pi 3-kinase and its up- and down-stream modulators as potential targets for the treatment of type II diabetes.

Bei B. Zhang, G. Jiang, 2002, Frontiers in bioscience : a journal and virtual library.

11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice

R. Thieringer, J. Metzger, B. Pikounis, 2005, The Journal of experimental medicine.

SAR exploration at the C-3 position of tetrahydro-β-carboline sstr3 antagonists.

Margaret S. Wu, M. Reibarkh, Yun-ping Zhou, 2016, Bioorganic & medicinal chemistry letters.

Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes

Margaret S. Wu, Yun-ping Zhou, E. Sherer, 2015, ACS medicinal chemistry letters.

Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.

J. Berger, Gaochao Zhou, Sanjeev Kumar, 2009, Bioorganic & medicinal chemistry letters.

Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonism.

J. Berger, D. Moller, T. Doebber, 2006, Endocrinology.

Small-molecule insulin mimetic reduces hyperglycemia and obesity in a nongenetic mouse model of type 2 diabetes.

D. Moller, D. Szalkowski, Bei B. Zhang, 2004, Endocrinology.

A small-molecule glucokinase activator lowers blood glucose in the sulfonylurea-desensitized rat.

Yun-ping Zhou, Bei B. Zhang, Hiroki Takano, 2010, European journal of pharmacology.

Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin.

G. Scapin, Suresh B. Singh, N. Thornberry, 2007, Bioorganic & medicinal chemistry letters.

Discovery of a small molecule insulin mimetic with antidiabetic activity in mice.

R G Smith, D. Moller, J. Zierath, 1999, Science.

A Model Selection Approach for Expression Quantitative Trait Loci (eQTL) Mapping

Eric E Schadt, I-Ming Wang, Ping Wang, 2011, Genetics.

Inhibition of adipocyte differentiation by HIV protease inhibitors.

J. Berger, D. Moller, B. Zhang, 1999, The Journal of clinical endocrinology and metabolism.

Activation of Insulin Signal Transduction Pathway and Anti-diabetic Activity of Small Molecule Insulin Receptor Activators*

D. Moller, D. E. Biazzo-Ashnault, V. Ding, 2000, The Journal of Biological Chemistry.

Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization.

S. O’Rahilly, J. Berger, D. Moller, 2002, Endocrinology.

Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1.

Margaret S. Wu, T. Doebber, D. Szalkowski, 2005, The Journal of clinical investigation.

Evidence that inhibition of insulin receptor signaling activity by PC-1/ENPP1 is dependent on its enzyme activity.

I. Wang, J. Berger, P. Lu, 2009, European journal of pharmacology.

11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.

R. Thieringer, J. Metzger, B. Pikounis, 2005, The Journal of experimental medicine.

Role of Skeletal Muscle in Thiazolidinedione Insulin Sensitizer ( PPAR g Agonist ) Action

J. Berger, D. Moller, J. Zierath, 1998 .